Video - Results from #30

ASCO 2021 VL

Long-Term Follow-Up From the KEYNOTE-052 Trial, Pembrolizumab in the First-Line Setting in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer – Arjun Balar Details In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD discussed the updated results of the KEYNOTE-052 trial up to 5 years of follow-up. KEYNOTE-052 was a multicentre, single-arm, phase 2 study that launched several years ago tested pembrolizumab in the first-line setting in cisplatin-ineligible patients with advanced urothelial cancer. The goal of KEYNOTE-052 was to evaluate the role...
Feladilimab Alone and in Combination with Pembrolizumab In Previously-Treated Urothelial Carcinoma Patients, An expansion Cohort of the INDUCE-1 Trial - Arjun Balar Details Arjun Balar, MD, joins Alicia Morgans, MD, MPH in a discussion on INDUCE-1, the a first-in-human trial evaluating feladilimab as monotherapy and in combination with pembrolizumab. In an oral abstract session at the 2021 ASCO annual meeting, Dr. Arjun Balar presented results of INDUCE-1 assessing preliminary efficacy, safety, and biomarker data of feladilimab ± pembrolizumab in urothelial carcinoma...
First Results of PEACE-1 A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone and/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cance... Details In a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi presented the first results of the PEACE-1 trial. PEACE-1 is a phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer. Adding abiraterone to ADT + docetaxel significantly impro...
Examining the Role of Docetaxel with Radiation Therapy and ADT in Non-Metastatic Prostate Cancer - Anthony D'Amico & Philip Kantoff Details Following androgen deprivation therapy (ADT) which was introduced decades prior, the TAX-327 trial of docetaxel for patients with metastatic castration-resistant prostate cancer was the first to demonstrate a survival advantage for systemic treatment in prostate cancer. Since then, docetaxel has proven survival benefit for men with metastatic castration-sensitive disease. However, the benefit of d...
The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor Details Oliver Sartor, MD, the CO-PI on the VISION Trial joins Alicia Morgans, MD, MPH in a conversation on the practice-changing VISION Trial results presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 177Lu-PSMA-617 is a targeted radioligand therapy that delivers ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment. The VISION study was an int...
KEYNOTE-564 Demonstrates Improvement in Disease-Free Survival - A New Standard of Care for High-Risk Kidney Cancer - Rana McKay Details Rana McKay, MD joins Alicia Morgans, MD, MPH in a discussion on the potential paradigm shift in the treatment landscape for high-risk kidney cancer with the findings from the KEYNOTE-564 trial. Dr. McKay was the discussant in the plenary session at the 2021 ASCO meeting following the presentation of the results by Toni Choueiri, MD. The phase 3 KEYNOTE-564 trial is a randomized, double-blind, plac...
177Lu-PSMA-617 Significantly Improves Overall Survival and Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer in VISION study - Mary-Ellen Taplin Details Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone. Mary-Ellen Taplin, Professor of Medicine and a GU Medical Oncologist at Dana-Farber Cancer Institute, joins Alicia Morga...
177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris Details In a plenary presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Michael Morris, MD, presented awaited results of the Phase III VISION trial. The study is evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard o...
Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - Scott Tagawa Details Scott Tagawa joins Alicia Morgans in a discussion on a Phase I study evaluating the tolerability of 225Ac-J591 in metastatic castration-resistant prostate cancer (mCRPC). This study was designed to determine the dose-limiting toxicity and the maximum tolerated dose of 225Ac-J591 in a single dose regimen of 225Ac-J591 that can be given without severe side effects. The initial dose-escalation portio...
Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas Details In this conversation with Alicia Morgans, MD, MPH, Petros Grivas, MD, PhD highlights the PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy has been found to improve overall survival in MIBC, but about half of patients...

ASCO 2021 VL

Login